DBV Technologies (NASDAQ:DBVT) Rating Lowered to Sell at Wall Street Zen

DBV Technologies (NASDAQ:DBVT) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

A number of other research analysts have also commented on DBVT. Guggenheim reaffirmed a “buy” rating and set a $51.00 price objective on shares of DBV Technologies in a research report on Monday, May 4th. HC Wainwright reaffirmed a “buy” rating on shares of DBV Technologies in a report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of DBV Technologies in a research note on Monday. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a research report on Friday, May 1st. Finally, Citizens Jmp raised their price target on shares of DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $48.50.

DBV Technologies Stock Performance

Shares of DBVT stock opened at $15.82 on Friday. The firm has a market capitalization of $936.70 million, a P/E ratio of -3.55 and a beta of -0.95. DBV Technologies has a 1 year low of $8.51 and a 1 year high of $26.18. The firm’s fifty day simple moving average is $17.97 and its 200 day simple moving average is $19.76.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.42). DBV Technologies had a negative net margin of 2,895.37% and a negative return on equity of 129.88%. The company had revenue of $0.90 million during the quarter, compared to the consensus estimate of $1.11 million. Equities research analysts anticipate that DBV Technologies will post -0.38 EPS for the current fiscal year.

Institutional Investors Weigh In On DBV Technologies

Several large investors have recently made changes to their positions in the company. Perceptive Advisors LLC bought a new stake in DBV Technologies during the first quarter worth about $20,146,000. Vivo Capital LLC increased its position in DBV Technologies by 8.4% in the 1st quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock valued at $55,726,000 after acquiring an additional 205,943 shares in the last quarter. ADAR1 Capital Management LLC bought a new position in shares of DBV Technologies in the first quarter worth about $21,159,000. Royal Bank of Canada raised its stake in shares of DBV Technologies by 167.1% in the first quarter. Royal Bank of Canada now owns 4,680 shares of the company’s stock worth $98,000 after acquiring an additional 2,928 shares during the last quarter. Finally, Elmind Capital LP bought a new position in shares of DBV Technologies in the first quarter worth about $5,536,000. Institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.